Source: Brown A, et al. EASL 2015; Abstract P0771.Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: Baseline CharacteristicsBaseline CharacteristicGenotype 2Genotype 4, 5, 6EBR + GZR+ RBV n=30GZR + RBV n=30EBR + GZR + RBVn=19EBR-GZRn=19Mean age, y (range)47.348.352.252.8Male sex, %63.356.742.163.2Race, % White Other100086.713.373.726.368.431.6HCV Genotype, n 2 4 5 6 130000--26000401044--01044--HCV RNA ≤ 2 million >2 million36.763.336.763.357.942.136.863.2*Excluded from modified intent-to-treat analysis due to discordant genotype